Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Thor6570on Jul 30, 2020 5:52am
112 Views
Post# 31341841

Back to Basics and facts !

Back to Basics and facts !

CONCLUSIONS

Combination of TLD1433 instillation and the use of green PDT activation light results in a steep PDT gradient providing one avenue to protect normal muscle function. The high selective uptake of TLD1433 is very favorable to compensate for heterogeneities in the bladder wall irradiance, and the absence of visible damage to the muscle layers also opens an avenue for the treatment of MIBC in addition to targeting NMIBC. Based on the threshold calculation, the selectivity of TLD1433 mediated PDT can be maintained over two penetration depths, possibly significantly more if the true tumor and urothelium threshold values can be determined for human cases. This is also very favorable as for human cases of MIBC, longer wavelength per target tissue penetration depth could be employed, mainly because of the apparent low TLD1433 concentrations in the muscle layers and the ability to activate the photosensitizer across a broad optical spectrum.

This study does not address possible caveats for the clinical translation of TLD1433 mediated PDT for NMIBC. For example, the urothelial layer over the tumor must be compromised for the photosensitizer to gain access to the malignant cells. Therefore, a tumor growing under an intact urothelial layer may not be sensitized by instillation alone. Also, NMIBC can be present upstream of the bladder, which is not targeted by PDT limited to intravesical illumination and bladder cancer cells as cancer cells may shed upstream and reseed on the bladder wall denuded of the urothelium, suggesting that for clinical use, repeat treatments may be advisable.

The excellent safety aspects, based on the large SUR, and the steep PDT gradient due to the use of short, green activation wavelength, makes TLD1433 mediated PDT an excellent candidate for NMIBC.

Evaluation of a Ruthenium coordination complex as photosensitizer for PDT of bladder cancer: Cellular response, tissue selectivity and in vivo response - Lilge - 2020 - Translational Biophotonics - Wiley Online Library

<< Previous
Bullboard Posts
Next >>